Tag Archives: nod.

Gilead’s Descovy nabs PrEP nod. Next step: Convert Truvada patients before generics hit

Clock’s ticking. After an expected FDA nod for Descovy as the second HIV PrEP drug, Gilead Sciences now has one year to convince its current Truvada takers to switch over before generics hit. The FDA approval is for Descovy use in men and transgender women for HIV prevention. The exclusion of cisgender women from the label… Read More »